OMX Ventures

Replay is a genome writing company focused on advancing genomic medicine by reprogramming biology through the writing and delivery of large DNA sequences. The company has developed a hypoimmunogenic induced pluripotent stem cell (iPSC) therapeutic platform, which aims to enhance the effectiveness of gene therapy and genome editing. By leveraging innovative technologies, Replay seeks to redefine the landscape of genetic treatments and improve patient outcomes in various therapeutic areas.

1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics. The company was founded in 2019 and is headquartered in San Diego, California.

Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.

At Sestina Bio, LLC their mission is to create a technology centric, R&D platform that will tackle some of the largest challenges of the 21st century and provide cutting edge solutions to sustainably feed, clothe, and keep healthy the growing world population. their approach is to integrate, and where needed create, the most innovative and novel advances in synthetic biology, data sciences, and bio-analytical systems.

Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

Matterworks is a biotech startup that combines metabolomics with AI to simulate the metabolic environment. The startup is enabling real-time insights into cellular biology to accelerate therapeutic research, development, and manufacturing with an AI-driven cloud platform for metabolomics. Matterworks was founded by Mimoun Cadosch Delmar and Jack Geremia in 2019.